Phosphodiesterases (PDEs) control cellular concentrations of cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). PDE4 and PDE5 selectively hydrolyze cAMP and cGMP, respectively. PDE family members share approximately 25% sequence identity within a conserved catalytic domain of about 300 amino acids. Crystal structure analysis of PDE4's catalytic domain identifies two metal-binding sites: a high-affinity site and a low-affinity site, which probably bind zinc (Zn 2 þ ) and magnesium (Mg 2 þ ), respectively. Absolute conservation among the PDEs of two histidine and two aspartic acid residues for divalent metal binding suggests the importance of these amino acids in catalysis. Although active sites of PDEs are apparently structurally similar, PDE4 is specifically inhibited by selective inhibitors such as rolipram, while PDE5 is preferentially blocked by sildenafil. Modeling interactions of the PDE5 inhibitor sildenafil with the PDE4 active site may help explain inhibitor selectivity and provide useful information for the design of new inhibitors.
Introduction
In all, 11 families of phosphodiesterase (PDE) have been identified in the human body. Each family of PDE exhibits a preference to either hydrolyze cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) to adenosine monophosphate (AMP) or to guanosine monophosphate (GMP), respectively. However, all 11 PDE families contain the conserved catalytic domain of approximately 300 amino acids, implying similar threedimensional structures of the catalytic domains.
The crystal structure of the catalytic domain of PDE4B (residues 152-528) revealed 17 alpha helices, which form three subdomains. 1 Subdomain 1, or the N-terminal domain, is composed of a group of seven a helices (H1-H7). Subdomain 2 is composed of four a helices (H8-H11). Subdomain 3 consists of five a helices (H12-H16) and an extended loop forming a b hairpin between H12 and H13.
The three subdomains jointly form a deep pocket. This pocket contains 12 of the 17 residues absolutely conserved across all PDE families. It is the only pocket on the enzyme with sufficient volume (about 450 Å 3 ) to accommodate a molecule with the size of cAMP (about 250 Å 3 ), and thus must serve as the catalytic pocket.
Helix 17 (residue 496-508) interacts with the residues of the catalytic pocket via a crystallographic symmetry in the crystal of PDE4B. However, this helix exists in a random conformation within the structure of PDE4D2. 2 The conformational variation of the C-terminal residues in the PDE4 family as well as the sequence diversity in the 11 PDE families may suggest a role for the C-terminus in the regulation of PDE hydrolytic activity. The sequence alignment of PDEs identified two conserved Hx 3 Hx 24-26 E sequences that are characteristic motifs for zinc binding, 3, 4 thus suggesting that PDE is a zinc enzyme. Indeed, biochemical studies have shown that a divalent metal is required for the catalytic activity of PDE. for PDE4A, 8 and three Zn 2 þ for PDE5. 9 The crystal structure has revealed that the active site of PDE4 contains a cluster of two metal atoms separated by about 3.9 Å , 1 and coordinates with two histidines and two aspartic acids. Diverging from the prediction that each Hx 3 Hx 24-26 E motif binds a metal ion, two Hx 3 Hx 24-26 E motifs jointly interact with two metal sites simultaneously. Since other motifs unlikely exist for the binding of divalent metals, two metals should apply to all families of PDE, as evidenced by the molecule's crystal structure.
The first metal atom sits at the bottom of the catalytic pocket and coordinates with two histidines (H164, H200 in PDE4D2) and two aspartic acids (Asp201 and Asp318). As these metal binding residues belong, respectively, to the three PDE4 subdomains, the apparent role of the metal is to stabilize the protein structure. On the other hand, recent study on the PDE4-AMP structure showed that the metal also interacts with the phosphate oxygen and thus strongly suggests a catalytic role. 10 The strong anomalous scattering at the wavelength of the zinc absorption edge suggests the first metal is a zinc, and is consistent with the fact that zinc, at low concentration, activates the enzyme. 9 In PDE4D2, the second metal ion coordinates with D318, a bound water, and possibly with the phosphate group of the substrate. Owing to the weak binding of the site, the type of the second divalent metal is difficult to assign, although magnesium (Mg) or manganese (Mn) is likely, according to biochemical studies (Figure 1) .
On the basis of the observations that all metalbinding residues are absolutely conserved in the PDE families, and that cAMP and cGMP contain a common phosphate group for the hydrolysis, a universal mechanism can be proposed for the hydrolysis of cAMP or cGMP by all families of PDE. Thus, two metal ions hold the phosphate group of cAMP in the active site and polarize the phosphor-oxygen bond to make the phosphor atom partially positively charged. The histidine (His160 in PDE4D2) that is absolutely conserved in all families of PDE would protonate the O3 0 group to further polarize the P-O bond for an easy nucleophilic attack. Finally, a hydroxide ion on water molecule that is bound to the metals and activated by aspartic acid attacks nucleophilically the phosphor atom to facilitate the catalysis.
Each PDE family possesses its own inhibitors that either weakly inhibit or do not crossly inhibit other PDE families. Selective inhibitors of PDEs have been rapidly identified and widely studied as cardiotonic agents, vasodilators, smooth muscle relaxants, antidepressants, antithrombotic compounds, antiasthma compounds, and agents for improving cognitive functions, such as memory. 11, 12 The FDA has approved several PDE inhibitors as therapeutic agents for human diseases. For example, sildenafil (Viagra s ) is a drug for male erectile dysfunction, and the PDE3 inhibitor cilostazol is a drug utilized in the treatment of intermittent claudication. However, it remains a mystery how selective PDE inhibitors that possess different chemical structures bind to apparently similar catalytic pockets.
Rolipram, an antidepressant available in Europe and Japan, selectively inhibits members of the PDE4 family. In fact, sensitivity to rolipram is considered a defining feature of this PDE family. Rolipram, cilomilast, and other inhibitors of PDE4 are thought to act by direct competition with the substrate. 13 They selectively inhibit PDE4 and increase the accumulation of cAMP. The degree of inhibition varies with the PDE4 subtypes. A direct correlation has been observed between the net loss of protein residue interactions and the degree of rolipram resistance in mutations. The positions of several drug sensitivity-determinant residues define a surface leading to the substrate-and drug-binding sites. This suggests that an approach channel leads to the active site.
Recently, the crystal structure of PDE4D, in complex with the inhibitor zardaverine, has been reported.
14 Zardaverine binds to the hydrophobic pocket of the active site in a mode of competition Figure 1 Ribbon presentation of the PDE4 catalytic domain.
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with the substrate cAMP, but does not directly interact with the metals. It forms two hydrogen bonds with Gln369 and interacts with residues Met273, Leu319, Ile336, Met337, Phe340, and Phe372 (PDE4D2 numbering). The fact that zardaverine is a dual inhibitor of PDE3 and PDE4 15 implies that the structural information of the active site of PDE4 may be useful for design of not only PDE4 selective inhibitors, but also of other PDE selective inhibitors.
To investigate selectivity, the PDE5 selective inhibitor sildenafil (Viagra s ) was docked into the catalytic pocket of PDE4D2 (Figure 2) . Sildenafil has the IC 50 value of approximately 1 nM against PDE5, and about 1000-fold selectivity of PDE5 over PDE4. 16 The model demonstrated an overall well fit of sildenafil into the catalytic pocket of PDE4. Thus, the purine-like ring of sildenafil sits in the hydrophobic pocket and forms a hydrogen bond, respectively, with Gln369 and Tyr159. However, Asn321, a residue showing dramatic variation across PDE families, collides with sildenafil.
On the basis of this model, alanine in PDE5, which corresponds to Asn321, is expected to make room for hydrophobic interactions with sildenafil. Thus, the same Asn to Ala mutation in PDE6 and PDE11 may explain their good sildenafil selectivity. The crystal structure of the catalytic domain of PDE4 provided valuable information on the active site of PDE4, and a potential guideline for design of subtype selective inhibitors toward PDE4. This knowledge may also influence future development of drugs selective to other PDEs, as shown by the docking of sildenafil into the PDE4 active site. Structure-based drug design may promote and facilitate discovery of highly selective inhibitors for each family of PDEs and thus dramatically improve the side-effect profile of PDE inhibitors.
A molecular basis for the side effects of drugs is their binding to nontargeted molecules. This is especially important because the human body contains over 60 isoforms of PDE. The substrate specificity and the inhibitor selectivity of the PDE families are two essential areas for further research on PDE inhibitors.
An outstanding question is whether inhibitor selectivity is determined by a few principal residues, or by subtle conformational differences at the active site of PDE, or by a combination of both. Although the PDE4 structures have clarified inhibitor selectivity to some degree, a thorough understanding of this phenomenon requires analysis of the molecular configurations of other PDE families. An additional unanswered issue hinges on the development of selective inhibitors against subtypes of a PDE family. The crystal structures of PDE4, in both their catalytic and regulatory domains, represent powerful tools for the design of subtypeselective inhibitors and a future direction for PDE inhibitor development.
